The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

Phase 1/2 Recruiting 90 enrolled Tianjin Medical University General Hospital Hebei Taihe Chunyu Biotechnology Co., Ltd · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.

Timeline

Start: 2024-11-09
Primary completion: 2026-02-28
Completion: 2027-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR19	Cell therapy	1e+06 cells/kg	Other
Subject	CAR19	Cell therapy	1.5e+06 cells/kg	Other
Subject	CAR19	Cell therapy	2e+06 cells/kg	Other
Subject	CAR19	Cell therapy	2.5e+06 cells/kg	Other
Subject	CAR19	Cell therapy	3e+06 cells/kg	Other
Subject	CAR2019	Cell therapy	1e+06 cells/kg	Other
Subject	CAR2019	Cell therapy	1.5e+06 cells/kg	Other
Subject	CAR2019	Cell therapy	2e+06 cells/kg	Other
Subject	CAR2019	Cell therapy	2.5e+06 cells/kg	Other
Subject	CAR2019	Cell therapy	3e+06 cells/kg	Other
Subject	CAR2219	Cell therapy	1e+06 cells/kg	Other
Subject	CAR2219	Cell therapy	1.5e+06 cells/kg	Other
Subject	CAR2219	Cell therapy	2e+06 cells/kg	Other
Subject	CAR2219	Cell therapy	2.5e+06 cells/kg	Other
Subject	CAR2219	Cell therapy	3e+06 cells/kg	Other

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

Summary

Timeline

Drugs

Indications